Newly developed synthetic porphyrin may be used as a dual antidote against fire gas poisoning

Written By :  Isra Zaman
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-02-21 04:15 GMT   |   Update On 2023-02-21 04:15 GMT

In a recent breakthrough, a team of researchers led by Professor Hiroaki Kitagishi from the Faculty of Science and Engineering, Doshisha University, Japan has developed a synthetic heme-model compound termed “hemoCD-Twins”, that acts as an antidote for CO and HCN poisoning. Prof. Kitagishi and his collaborators-Dr. Qiyue Mao from Doshisha University, Dr. Xuansu Zhao from the Building Research Institute, Japan, Dr. Akiko Kiriyama from Doshisha Women’s College of Liberal Arts, Japan, and Dr. Roberto Motterlini from University Paris Est Creteil, France-have detailed the development of this novel antidote in their recent research article published in the Proceedings of the National Academy of Sciences (PNAS). In saline solution, hemoCD Twins dissolves into two heme models, of which hemoCD-P captures CO very strongly, and hemoCD-I effectively scavenges CN-.

Buildings across the globe are prone to catching fires in unfortunate situations. Other than the flames, the burning materials generate highly toxic carbon monoxide (CO) and hydrogen cyanide (HCN) gases, which can be fatal upon ingestion. Once inhaled, these gases bind strongly to hemoglobin, cytochromes, and iron containing compounds known as “hemes”, and block normal aerobic respiration. It is believed that once an individual is exposed to these life-threatening toxins, it is impossible to effectively remove them from the body. In fact, at present, there is no therapeutic approach available to overcome simultaneous CO and HCN poisoning. This poses a significant challenge in saving lives of people exposed to toxic gases in building fires.

Advertisement

What was the motivation behind the development of this life-saving compound? Prof. Kitagishi recalls, “We have been studying synthetic heme-model compounds (hemoCDs) for over two decades. The series of hemoCDs, which comprises a mixture of synthetic organic compounds—porphyrin and cyclodextrins—has been our original heme-model system that realizes the biological functions of hemes using completely synthetic materials. One fine morning during the course of our research, I embarked on the idea that hemoCDs could be best used as antidotes against simultaneous poisoning by CO and HCN.”

The team has also demonstrated hemoCD-Twins to be a very effective and rapid antidote against CO and HCN simultaneous poisoning in mice models. They found that in mice, this compound resulted in an 85% survival rate and rapid recovery. Moreover, this dual antidote exhibited very low toxicity and rapid elimination via urinary excretion. In addition, hemoCD-Twins had an immediate antidotal effect, a high degree of safety, and storage stability.

How will this antidote impact our lives in the long run? Prof. Kitagishi muses, “This antidote will limit damage from gas poisoning caused by sudden fires and can be tested for the treatment of various symptoms caused by gas poisoning. With the completion of various non-clinical and clinical trials, within 5–10 years, we hope that hemoCD-Twins can be incorporated in ambulances, emergency hospitals, and other facilities. This way, future generations will have no need to fear sudden fire gas poisoning. We will proceed with non-clinical and clinical trials in cooperation with medical doctors in order to implement this compound as a therapeutic agent in the world. For this purpose, we would like to request the cooperation from the general society.” Here’s hoping that we see Prof. Kitagishi’s vision for hemoCD-Twins to be used as a powerful antidote come to life!

Reference:

A synthetic porphyrin as an effective dual antidote against carbon monoxide and cyanide poisoning,Proceedings of the National Academy of Sciences,doi 10.1073/pnas.2209924120

Full View
Tags:    
Article Source : Proceedings of the National Academy of Sciences

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News